ajm300 and Inflammatory-Bowel-Diseases

Our growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has opened new avenues for developing targeted therapies. These advances in treatment options targeting different mechanisms of action offer new hope for personalized management. In this review we highlight emerging novel and easily administered therapeutics that may be viable candidates for the management of IBD, such as antibodies against interleukin 6 (IL-6) and IL-12/23, small molecules including Janus kinase inhibitors, antisense oligonucleotide against SMAD7 mRNA, and inhibitors of leukocyte trafficking to intestinal sites of inflammation (e.g., sphingosine 1-phosphate receptor modulators). We also provide an update on the current status in clinical development of these new classes of therapeutics.

Topics: Animals; Antibodies, Monoclonal, Humanized; Humans; Indans; Inflammatory Bowel Diseases; Interleukin-23; Interleukin-6; Janus Kinase 1; Oligonucleotides, Antisense; Oxadiazoles; Phenylalanine; Precision Medicine; Quinazolinones; Quinolones; Smad7 Protein

Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including integrins and chemokine receptors, have been successfully targeted for the treatment of IBD. These agents have shown great promise for the induction and maintenance of remission for both Crohn disease and ulcerative colitis. This article discusses currently approved prototypic agents for the treatment of IBD (natalizumab, anti-α4 integrin; vedolizumab, anti-α4β7 integrin), and several other agents in the same class currently under development.

Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Adhesion Molecules; Gastrointestinal Agents; Humans; Immunoglobulins; Inflammatory Bowel Diseases; Integrins; Intercellular Adhesion Molecule-1; Mucoproteins; Natalizumab; Phenylalanine; Phosphorothioate Oligonucleotides; Quinazolinones; Receptors, CCR; Sulfonamides